Alcon to Launch Clareon IOL at ESCRS Meeting

October 6, 2017: By Joan McKenna

alcon-large-3x2Alcon will introduce its new Clareon intraocular lens (IOL) at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, set for Oct. 7-11 in Lisbon, Portugal.

The company describes the Clareon as having the most advanced optic IOL material available. The lens is offered in an automated, disposable, preloaded delivery system.

Alcon, the Texas-based eye care division of Novartis, says it will provide an extensive scientific and educational program at the meeting, with 18 accepted abstracts and more than 10 satellite events.

“We are proud to deliver on our commitment to bring innovations to the surgical community, and Clareon is one of the biggest breakthroughs in the IOL space,” said Mike Ball, chief executive officer of Alcon. “This is a great year for Alcon as we celebrate many important milestones.”

Among those is the 100 millionth implantation of Alcon’s flagship AcrySof lens, Ball said.

Presentations also will include new efficacy and safety data for Alcon’s CyPass Micro-Stent in patients with glaucoma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022